Published in Cancer Res on October 01, 1975
Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer (1989) 1.97
Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol (1986) 1.97
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther (2010) 1.34
A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Br J Cancer (2005) 1.21
The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis (2013) 1.17
Tumor cell growth fraction in Hodgkin's disease. Am J Pathol (1987) 1.05
Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br J Cancer (2005) 1.05
Silk-elastinlike protein polymer hydrogels for localized adenoviral gene therapy of head and neck tumors. Biomacromolecules (2009) 0.98
Cell cycle-arrested tumor cells exhibit increased sensitivity towards TRAIL-induced apoptosis. Cell Death Dis (2013) 0.92
Immunohistological determination of proliferative activity in seminomas. J Clin Pathol (1988) 0.88
Demonstration of vincristine resistance in primary intestinal neoplasms in the rat by the 'post-metaphase index'. Br J Cancer (1985) 0.88
Cytotoxic effect in vivo of selected chemotherapeutic agents on synchronized murine fibrosarcoma cells. Br J Cancer (1980) 0.85
Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer (2002) 0.85
Acquired resistance to cancer chemotherapy. Br Med J (Clin Res Ed) (1984) 0.84
Radiation response of proliferating and quiescent subpopulations isolated from multicellular spheroids. Br J Cancer (1986) 0.82
An acidic microenvironment increases NK cell killing of Cryptococcus neoformans and Cryptococcus gattii by enhancing perforin degranulation. PLoS Pathog (2013) 0.82
New insights into the kinetic resistance to anticancer agents. Cytotechnology (1998) 0.82
Role of laboratory chemosensitivity testing in the selection of cancer chemotherapy for individual patients. J Clin Pathol (1981) 0.82
Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity. Environ Health Perspect (1998) 0.79
Targeting enzymes for cancer therapy: old enzymes in new roles. Br J Cancer (1994) 0.79
Cell surface tubulin in leukemic cells: molecular structure, surface binding, turnover, cell cycle expression, and origin. J Cell Biol (1985) 0.78
Prediction of Cancer Drug Resistance and Implications for Personalized Medicine. Front Oncol (2015) 0.77
Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells. Glycobiology (2015) 0.77
Targeting Lung Cancer Stem Cells: Research and Clinical Impacts. Front Oncol (2017) 0.77
Cell fusion to study nuclear-cytoplasmic interactions in endothelial cell apoptosis. Am J Pathol (1996) 0.77
Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer. Oncotarget (2015) 0.76
Responses of proliferating and non-proliferating Chinese hamster cells to cytotoxic agents. Br J Cancer (1978) 0.76
Cytokinetic factors in drug resistance of Lewis lung carcinoma: comparison of cells freshly isolated from tumours with cells from exponential and plateau-phase cultures. Br J Cancer (1987) 0.75
Combination therapy induces unfolded protein response and cytoskeletal rearrangement leading to mitochondrial apoptosis in prostate cancer. Mol Oncol (2016) 0.75
An inverse relationship between the growth rate of human melanoma xenografts and their response to some cytostatic drugs. Br J Cancer (1980) 0.75
Role of oxygenation and vascularization in drug resistance. Cytotechnology (1998) 0.75
Synergistic effect of amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea against a transplantable AKR leukemia. Cancer Res (1974) 1.52
Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs (1986) 1.41
Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother Rep (1976) 1.28
Combined effect of x radiation and 5-fluorouracil on survival of transplanted leukemic cells. J Natl Cancer Inst (1971) 1.17
5-Fluorouracil (FUra). Pharmacol Ther (1984) 1.04
Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Invest New Drugs (1997) 1.02
Protective effects of amphotericin B against spontaneous and transplantable murine tumors. J Natl Cancer Inst (1976) 0.93
The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate. Cancer Res (1975) 0.88
Survival of hematopoietic and leukemic colony-forming cells in vivo following the administration of daunorubicin or adriamycin. Cancer Res (1972) 0.88
In vivo potentiation of 5-fluorouracil cytotoxicity against AKR leukemia by purines, pyrimidines, and their nucleosides and deoxynucleosides. J Natl Cancer Inst (1980) 0.87
Marked histoincompatibility between and within sublines of AKR mice used in a syngeneic leukemia model. J Natl Cancer Inst (1975) 0.87
Activity of batracylin (NSC-320846) against solid tumors of mice. Invest New Drugs (1989) 0.86
A randomized trial of a low-fat dietary intervention in women at high risk for breast cancer. Nutr Cancer (1997) 0.85
Schedule-dependent synergism for the combination of 1-beta-D-arabinofuranosylcytosine and daunorubicin. Cancer Res (1974) 0.83
Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent. Cancer Chemother Pharmacol (1987) 0.83
Optimum time sequence for the administration of vincristine and cyclophosphamide in vivo. Cancer Res (1974) 0.82
Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res (1982) 0.82
Cellular uptake of a novel cytotoxic agent, cryptophycin-52, by human THP-1 leukemia cells and H-125 lung tumor cells. Int J Cancer (1998) 0.81
Cellular aspects of the action of cytosine arabinoside. Med Pediatr Oncol (1982) 0.81
Potentiation of anticancer agent cytotoxicity against sensitive and resistant AKR leukemia by amphotericin B1. Cancer Res (1979) 0.81
In vivo enhancement of 5-fluorouracil cytotoxicity to AKR leukemia cells by thymidine in mice. J Natl Cancer Inst (1978) 0.80
Response of transplanted AKR leukemia to combination therapy with amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea: dose and schedule dependency. J Natl Cancer Inst (1977) 0.80
Application of flow cytometry and cell sorting to megakaryocytopoiesis. Blood (1979) 0.80
Potentiation of anticancer agents by amphotericin B. J Natl Cancer Inst (1981) 0.79
Phase I study and pharmacokinetics of weekly high-dose 13-cis-retinoic acid. Cancer Res (1985) 0.78
Potentiation of cytotoxicity of anticancer agents by several different polyene antibiotics. J Natl Cancer Inst (1984) 0.78
Extensive proliferative capacity of haematopoietic stem cells. Cell Tissue Kinet (1983) 0.78
In vivo DNA cross-linking by cyclophosphamide: comparison of human chronic lymphatic leukemia cells with mouse L1210 leukemia and normal bone marrow cells. Cancer Res (1989) 0.77
Regulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors in a GM-CSF-dependent human myeloid leukemia cell line (AML-193) by interleukin-6. Exp Hematol (1996) 0.77
Chemical modification of radiation and chemotherapy. Am J Clin Oncol (1988) 0.77
Kinetics of both leukemic and normal cell population reduction following 5-azacytidine. Cancer Res (1975) 0.77
Kinetics of the lethal effect of actinomycin D on normal and leukemic cells. Cancer Res (1973) 0.76
Discrepancy between cytotoxicity and DNA interstrand crosslinking of carboplatin and cisplatin in vivo. Invest New Drugs (1990) 0.76
Flavone acetic acid and plasma protein binding. Cancer Chemother Pharmacol (1990) 0.76
Growth characteristics of MOPC-315 plasmacytoma and response to anticancer agents. J Natl Cancer Inst (1981) 0.76
Contrasting cytotoxicity kinetics of 5-azacytidine and dihydro-5-azacytidine hydrochloride in L1210 leukemia in mice. J Natl Cancer Inst (1981) 0.76
Amphotericin B potentiation of the cytotoxicity of anticancer agents against both normal hematopoietic and leukemia cells in mice. J Natl Cancer Inst (1984) 0.76
Biological characterization of a prolonged antileukemic effect of 5-azacytidine. Cancer Res (1977) 0.76
Survival of hematopoietic and leukemic colony-forming cells in vivo after administration of mitomycin C or porfiromycin. J Natl Cancer Inst (1973) 0.75
Schedule-dependent potentiation of lomustine cytotoxicity by amphotericin B in mice. J Natl Cancer Inst (1986) 0.75
Studies on the structure of tyrosine aminotransferase. Biochim Biophys Acta (1970) 0.75
Survival of L1210 leukemia cells and normal hematopoietic stem cells following in vivo administration of cyclocytidine. Invest New Drugs (1985) 0.75
Influence of continuous infusion of cytosine arabinoside on sequencing with daunorubicin in L1210 leukemia. Cancer Treat Rep (1978) 0.75
Growth and rejection of leukemia cells in individual mice after combined treatment with amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea. J Natl Cancer Inst (1978) 0.75
Dose and interval relationship for the interaction of WR-2721 and nitrogen mustard with normal and malignant cells. Int J Radiat Oncol Biol Phys (1984) 0.75
Interaction between flavone acetic acid (LM-975, NSC 349512) and radiation in Glasgow's osteogenic sarcoma in vivo. Int J Radiat Oncol Biol Phys (1990) 0.75
Quantitative measurements of the efficacy of new anti-cancer agents on fresh human AML cells by using multivariate flow analysis. J Exp Ther Oncol (1996) 0.75
Retention of 1-beta-D-arabinofuranosylcytosine in vitro--a source of experimental error. Biochem Pharmacol (1977) 0.75
Experimental studies on the combination of radiation and chemotherapy. Int J Radiat Oncol Biol Phys (1978) 0.75
Comparison of the cytotoxicity of 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) on normal and leukemic colony-forming cells. Cancer Chemother Rep (1971) 0.75
Cellular quantitation of in vivo effects of 1-beta-D-arabinofuranosylcytosine on leukemia L1210. J Natl Cancer Inst (1977) 0.75
Effect of dose fractionation of daunorubicin on survival of leukemic cells. Cancer Res (1980) 0.75
Cytotoxicity of adriamycin combined with methotrexate against L1210 leukemia in mice. J Natl Cancer Inst (1980) 0.75
Actinomycin D: kinetics of its lethal action on a transplantable leukemia. J Natl Cancer Inst (1971) 0.75
Potentiation of nitrogen mustard cytotoxicity to leukemia cells by sulfur-containing compounds administered in vivo. Int J Radiat Oncol Biol Phys (1986) 0.75
MOPC-315 murine plasmacytoma as a model anticancer screen for human multiple myeloma. J Natl Cancer Inst (1986) 0.75
Quantitation of the immune rejection of allotransplanted AKR leukemic cells. Transplantation (1976) 0.75
Analysis of MOPC-315 plasmacytoma by elutriation and flow cytometry. Cell Tissue Kinet (1984) 0.75
A murine model for central nervous system leukemia and its possible relevance to human leukemia. J Natl Cancer Inst (1975) 0.75
In vitro screening model for the detection of agents active against myelogenous leukemia. Cancer Invest (1998) 0.75
Combined effect of cytosine arabinoside and thiopurines. Cancer Treat Rep (1976) 0.75
Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside. J Natl Cancer Inst (1981) 0.75
Potentiation by amphotericin B of the cytotoxicity of anticancer agents against MOPC-315 plasmacytoma and Lewis lung carcinoma. Cancer Chemother Pharmacol (1984) 0.75
Cytotoxic effect of 5-fluorouracil plus cyclophosphamide against transplantable leukemias. Eur J Cancer (1981) 0.75
Cytosine arabinoside in experimental combination therapy. Semin Oncol (1985) 0.75
Schedule-dependent antitumor and toxic effects of thymidine and 5-fluorouracil in AKR and L1210 leukemias. Cancer Chemother Pharmacol (1986) 0.75
Schedule-dependent cytotoxicity of 5-fluorouracil in mice. J Natl Cancer Inst (1986) 0.75
Comparison of cytotoxicity of single dose and infusion of alkylating agents. Cancer Drug Deliv (1985) 0.75